Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

THE STRATUS TRIAL (MM-010): ANALYSIS OF THE ITALIAN SUBGROUP OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE

Autor: Cavo, M, Corradini, P, DI RAIMONDO, Francesco, Vacca, A, Petrini, M, Cafro, Am, di Toritto TC, Offidani, M, Semenzato, G, Zambello, R, Lazzaro, A, Patriarca, F, Petrucci, Mt, Rodeghiero, F, Simcock, M, Slaughter, A, Herring, J, Peluso, T, Palumbo, A.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4731::4e0a504746771f4dd0958ac47d2cd24a
http://hdl.handle.net/20.500.11769/47578

THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Autor: Dimopoulos, Ma, Palumbo, A, Corradini, P, Cavo, M, Delforge, M, Weisel, K, Ocio, E, DI RAIMONDO, Francesco, Oriol, A, Simcock, M, Miller, N, Slaughter, A, Peluso, T, Sternas, L, Zaki, M, Moreau, P.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4731::57959c03c23f1fc70280a342e92234ad
http://hdl.handle.net/20.500.11769/44950

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

Autor: Von Moos, R, Seifert, B, Simcock, M, Goldinger, S M, Gillessen, S, Ochsenbein, A, Michielin, O, Cathomas, R, Schläppi, M, Moch, H, Schraml, P H, Mjhic-Probst, D, Mamot, C, Schönewolf, N, Dummer, R, Swiss Group For Clinical Cancer Research (SAKK)

Publikováno v: Annals of Oncology, vol. 23, no. 2, pp. 531-6
von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mjhic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R; Swiss Group for Clinical Cancer Research, (SAKK) (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of oncology, 23(2), pp. 531-6. Oxford: Oxford University Press 10.1093/annonc/mdr126

BACKGROUND: Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b6ae54e22900ca625e09bbc35c5b62
https://pubmed.ncbi.nlm.nih.gov/21527587

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.